Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 17, 2024JAMA Network OpenOpen Access

In-Hospital Use of Long-Acting Injectable Antipsychotics and Readmission Risk in Patients With First-Admission Schizophrenia in Taiwan

View Full Paper
Ask AI
Bookmark
Share

Authors

WCWei J. ChenNational Chung Cheng UniversityCWChi‐Shin WuNational Taiwan University HospitalCLChen‐Chung LiuNational Taiwan University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Chen et al. (2024) studied this question.

synapsesocial.com/papers/68e64677b6db6435875d7804https://doi.org/10.1001/jamanetworkopen.2024.17006
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparative Effectiveness of Antipsychotics in Preventing Readmission for First-Admission Schizophrenia Patients in National Cohorts From 2001 to 2017 in Taiwan2022 · 21 citations
  2. 2Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia2015 · 262 citations
  3. 3A Randomized Controlled Trial of Long-Acting Injectable Risperidone vs Continuation on Oral Atypical Antipsychotics for First-Episode Schizophrenia Patients2009 · 107 citations
  4. 4Canadian Treatment Guidelines on Psychosocial Treatment of Schizophrenia in Adults2017 · 97 citations
  5. 5Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available: Table 1.2016 · 3,098 citations